State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
EBioMedicine. 2022 Jul;81:104100. doi: 10.1016/j.ebiom.2022.104100. Epub 2022 Jun 8.
Distant metastasis remains the leading cause of treatment failure in patients with nasopharyngeal carcinoma (NPC), making it critical to identify efficient therapeutic targets for metastatic NPC. Previous studies have demonstrated that deoxynucleotidyltransferase terminal-interacting protein 1 (DNTTIP1) is associated with the development of various types of cancer. However, its role and mechanism in NPC have not been explored.
RNA-seq profiling was performed for three pairs of NPC and normal nasopharynx tissues. DNTTIP1 expression in NPC specimens was detected by immunohistochemistry. In vitro and in vivo assays were used to investigate the function of DNTTIP1. The molecular mechanism was determined using RT-qPCR, western blotting, RNA-seq, luciferase reporter assays, ChIP assays, and co-IP assays.
DNTTIP1 was found to be significantly upregulated in NPC tissues. Furthermore, DNTTIP1 promoted NPC growth and metastasis in vitro and in vivo. Upregulation of DNTTIP1 in NPC indicated poor clinical outcomes. Mechanistically, DNTTIP1 suppressed DUSP2 gene expression via recruiting HDAC1 to its promoter and maintaining a deacetylated state of histone H3K27. The downregulation of DUSP2 resulted in aberrant activation of the ERK signaling and elevated MMP2 levels, promoting NPC metastasis. Chidamide, an HDAC inhibitor, was shown to suppress NPC metastasis by regulating the DNTTIP1/HDAC1-DUSP2 axis.
Our findings demonstrate that DNTTIP1 not only regulates NPC metastasis but also independently predicts NPC prognosis. Furthermore, targeting DNTTIP1/HDAC1 by Chidamide may benefit NPC patients with metastasis.
This work was supported by the National Natural Science Foundation of China (No. 81872464, 82073243).
远处转移仍然是鼻咽癌(NPC)患者治疗失败的主要原因,因此确定转移性 NPC 的有效治疗靶点至关重要。先前的研究表明,脱氧核苷酸转移酶末端相互作用蛋白 1(DNTTIP1)与多种类型的癌症的发展有关。然而,其在 NPC 中的作用和机制尚未得到探索。
对三对 NPC 和正常鼻咽组织进行 RNA-seq 分析。通过免疫组织化学检测 NPC 标本中 DNTTIP1 的表达。采用体外和体内实验研究 DNTTIP1 的功能。通过 RT-qPCR、western blot、RNA-seq、荧光素酶报告基因检测、ChIP 实验和 co-IP 实验确定分子机制。
发现 DNTTIP1 在 NPC 组织中显著上调。此外,DNTTIP1 在体外和体内促进 NPC 的生长和转移。DNTTIP1 在 NPC 中的上调预示着较差的临床结局。机制上,DNTTIP1 通过募集 HDAC1 到其启动子并维持组蛋白 H3K27 的去乙酰化状态来抑制 DUSP2 基因的表达。DUSP2 的下调导致 ERK 信号的异常激活和 MMP2 水平的升高,从而促进 NPC 的转移。HDAC 抑制剂 Chidamide 通过调节 DNTTIP1/HDAC1-DUSP2 轴来抑制 NPC 的转移。
我们的研究结果表明,DNTTIP1 不仅调节 NPC 的转移,而且独立预测 NPC 的预后。此外,通过 Chidamide 靶向 DNTTIP1/HDAC1 可能有益于 NPC 转移患者。
本工作得到国家自然科学基金(No. 81872464, 82073243)的支持。